{'fraction_non_alphanumeric': 0.022700119474313024, 'fraction_numerical': 0.0, 'mean_word_length': 6.042016806722689, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.

Introduction The approval by the US Food and Drug Administration of ipilimumab (Yervoy; Bristol-Myers Squibb, Princeton, New Jersey) expanded the therapeutic options for treating patients with metastatic melanoma. However, for patients with a history of an autoimmune disorder or organ transplantation, options for therapy are more limited. Here, we describe the successful administration of ipilimumab to two patients with metastatic melanoma, each of whom had previously undergone kidney transplantation. In both cases, the patients remained on low-dose immunosuppression during ipilimumab therapy. Kidney function was monitored closely and remained stable throughout treatment. Both patients experienced benefit from ipilimumab.